Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given an average rating of “Hold” by the nine ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.75.

Several brokerages recently weighed in on ELAN. Barclays increased their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. UBS Group started coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price target for the company. Finally, Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of ELAN. Commerce Bank boosted its position in Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after acquiring an additional 741 shares in the last quarter. HBK Sorce Advisory LLC boosted its position in shares of Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after purchasing an additional 1,107 shares in the last quarter. Atomi Financial Group Inc. grew its stake in Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock worth $177,000 after purchasing an additional 1,221 shares during the period. Keene & Associates Inc. raised its holdings in Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after purchasing an additional 1,240 shares in the last quarter. Finally, Resonant Capital Advisors LLC lifted its position in Elanco Animal Health by 5.0% during the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company’s stock valued at $394,000 after buying an additional 1,306 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 3.9 %

ELAN stock opened at $12.10 on Monday. The company has a market capitalization of $5.98 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a one year low of $11.40 and a one year high of $18.80. The company’s 50 day moving average price is $13.22 and its two-hundred day moving average price is $14.30.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company earned $0.18 EPS. The firm’s revenue was down 3.6% compared to the same quarter last year. As a group, analysts predict that Elanco Animal Health will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.